An ‘Omics’ Perspective on Cardiomyopathies and Heart Failure

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

Pathological enlargement of the heart, represented by hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM), occurs in response to many genetic and non-genetic factors. The clinical course of cardiac hypertrophy is remarkably variable, ranging from lifelong absence of symptoms to rapidly declining heart function and sudden cardiac death (SCD). Unbiased omics studies have begun to provide a glimpse into the molecular framework underpinning altered mechanotransduction, mitochondrial energetics, oxidative stress, and extracellular matrix in the heart undergoing physiological and pathological hypertrophy. Omics analyses indicate that post-transcriptional regulation of gene expression plays an overriding role in the normal and diseased heart. Studies to date highlight a need for more effective bioinformatics to better integrate patient omics data with their comprehensive clinical histories.

Original languageEnglish (US)
Pages (from-to)813-827
Number of pages15
JournalTrends in Molecular Medicine
Volume22
Issue number9
DOIs
StatePublished - Sep 1 2016

Fingerprint

Cardiomegaly
Cardiomyopathies
Heart Failure
Hypertrophic Cardiomyopathy
Sudden Cardiac Death
Dilated Cardiomyopathy
Gene Expression Regulation
Computational Biology
Hypertrophy
Extracellular Matrix
Heart Diseases
Oxidative Stress

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Molecular Biology

Cite this

An ‘Omics’ Perspective on Cardiomyopathies and Heart Failure. / Raghow, Rajendra.

In: Trends in Molecular Medicine, Vol. 22, No. 9, 01.09.2016, p. 813-827.

Research output: Contribution to journalReview article

@article{46b05ba544554bf9bbdc2e26f2cb6109,
title = "An ‘Omics’ Perspective on Cardiomyopathies and Heart Failure",
abstract = "Pathological enlargement of the heart, represented by hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM), occurs in response to many genetic and non-genetic factors. The clinical course of cardiac hypertrophy is remarkably variable, ranging from lifelong absence of symptoms to rapidly declining heart function and sudden cardiac death (SCD). Unbiased omics studies have begun to provide a glimpse into the molecular framework underpinning altered mechanotransduction, mitochondrial energetics, oxidative stress, and extracellular matrix in the heart undergoing physiological and pathological hypertrophy. Omics analyses indicate that post-transcriptional regulation of gene expression plays an overriding role in the normal and diseased heart. Studies to date highlight a need for more effective bioinformatics to better integrate patient omics data with their comprehensive clinical histories.",
author = "Rajendra Raghow",
year = "2016",
month = "9",
day = "1",
doi = "10.1016/j.molmed.2016.07.007",
language = "English (US)",
volume = "22",
pages = "813--827",
journal = "Trends in Molecular Medicine",
issn = "1471-4914",
publisher = "Elsevier Limited",
number = "9",

}

TY - JOUR

T1 - An ‘Omics’ Perspective on Cardiomyopathies and Heart Failure

AU - Raghow, Rajendra

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Pathological enlargement of the heart, represented by hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM), occurs in response to many genetic and non-genetic factors. The clinical course of cardiac hypertrophy is remarkably variable, ranging from lifelong absence of symptoms to rapidly declining heart function and sudden cardiac death (SCD). Unbiased omics studies have begun to provide a glimpse into the molecular framework underpinning altered mechanotransduction, mitochondrial energetics, oxidative stress, and extracellular matrix in the heart undergoing physiological and pathological hypertrophy. Omics analyses indicate that post-transcriptional regulation of gene expression plays an overriding role in the normal and diseased heart. Studies to date highlight a need for more effective bioinformatics to better integrate patient omics data with their comprehensive clinical histories.

AB - Pathological enlargement of the heart, represented by hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM), occurs in response to many genetic and non-genetic factors. The clinical course of cardiac hypertrophy is remarkably variable, ranging from lifelong absence of symptoms to rapidly declining heart function and sudden cardiac death (SCD). Unbiased omics studies have begun to provide a glimpse into the molecular framework underpinning altered mechanotransduction, mitochondrial energetics, oxidative stress, and extracellular matrix in the heart undergoing physiological and pathological hypertrophy. Omics analyses indicate that post-transcriptional regulation of gene expression plays an overriding role in the normal and diseased heart. Studies to date highlight a need for more effective bioinformatics to better integrate patient omics data with their comprehensive clinical histories.

UR - http://www.scopus.com/inward/record.url?scp=84990913620&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84990913620&partnerID=8YFLogxK

U2 - 10.1016/j.molmed.2016.07.007

DO - 10.1016/j.molmed.2016.07.007

M3 - Review article

VL - 22

SP - 813

EP - 827

JO - Trends in Molecular Medicine

JF - Trends in Molecular Medicine

SN - 1471-4914

IS - 9

ER -